Wednesday, July 8, 2026

pharma · Hematologic Malignancies · Solid Tumor, Adult

Farmatek

Farmatek is a pharma organization headquartered in Istanbul, JP. Primary therapeutic focus areas include Hematologic Malignancies, Solid Tumor, Adult, Lymphoma, B-Cell, B-cell Mediated Autoimmune Diseases, COPD. NovaPhar

Aydınlı - KOSB Mah. Tuzla Kimya Sanayicileri Org. San. Böl. Analitik Cad. No:90 Tuzla, Istanbul, TR, JP HQ
1994 Founded
14 Employees
PMDA registrant Type
Company details
Status
Public
HQ
Aydınlı - KOSB Mah. Tuzla Kimya Sanayicileri Org. San. Böl. Analitik Cad. No:90 Tuzla, Istanbul, TR, JP
Founded
1994
Employees
14
Programs
26
Drugs
14
Patents
53
Clinical program

ProTmune

Phase 2 · mab · Hematologic Malignancies

ProTmune for Hematologic Malignancies is a Phase 2 program (mab) at Zafatek with 1 ClinicalTrials.gov record(s).

← All Zafatek projects Phase 2 mab completed

Internal code PT-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Zafatek
Phase
Phase 2
Modality
mab
Indication
Hematologic Malignancies
Status
completed
Trials
1

Clinical trials